Literature DB >> 23822858

A single dose of lipopolysaccharide into mice with emphysema mimics human chronic obstructive pulmonary disease exacerbation as assessed by micro-computed tomography.

Satoshi Kobayashi1, Reiko Fujinawa, Fumi Ota, Shiho Kobayashi, Takashi Angata, Manabu Ueno, Toshitaka Maeno, Shinobu Kitazume, Keiichi Yoshida, Takeo Ishii, Congxiao Gao, Kazuaki Ohtsubo, Yoshiki Yamaguchi, Tomoko Betsuyaku, Kozui Kida, Naoyuki Taniguchi.   

Abstract

Chronic obstructive pulmonary disease (COPD), manifested as emphysema and chronic airway obstruction, can be exacerbated by bacterial and viral infections. Although the frequency of exacerbations increases as the disease progresses, the mechanisms underlying this phenomenon are largely unknown, and there is a need for a simple in vivo exacerbation model. In this study, we compared four groups of mice treated with PBS alone, elastase alone, LPS alone, and elastase plus LPS. A single intratracheal administration of LPS to mice with elastase-induced emphysema provoked infiltration of inflammatory cells, especially CD8(+) T cells, into alveolar spaces and increased matrix metalloproteinase-9, tissue inhibitor of metalloproteinase-1, and perforin production in bronchoalveolar lavage fluid at the acute inflammatory phase compared with the other groups. We also measured the percentage of low-attenuation area (LAA%) in the above mice using micro-computed X-ray tomography. The LAA% was the most sensitive parameter for quantitative assessments of emphysema among all the parameters evaluated. Using the parameter of LAA%, we found significantly more severe alveolar destruction in the group treated with elastase plus LPS compared with the other groups during long-term longitudinal observations. We built three-dimensional images of the emphysema and confirmed that the lungs of elastase plus LPS-treated mice contained larger emphysematous areas than mice treated with elastase alone. Although human exacerbation of COPD is clinically and pathologically complicated, this simple mouse model mimics human cases to some extent and will be useful for elucidating its mechanism and developing therapeutic strategies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23822858     DOI: 10.1165/rcmb.2013-0074OC

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  29 in total

1.  Coactivator-Associated Arginine Methyltransferase-1 Function in Alveolar Epithelial Senescence and Elastase-Induced Emphysema Susceptibility.

Authors:  Rim S J Sarker; Gerrit John-Schuster; Alexander Bohla; Kathrin Mutze; Gerald Burgstaller; Mark T Bedford; Melanie Königshoff; Oliver Eickelberg; Ali Ö Yildirim
Journal:  Am J Respir Cell Mol Biol       Date:  2015-12       Impact factor: 6.914

2.  Why do we need a nonhuman primate model of smoking-induced COPD?

Authors:  Jeffrey L Curtis; Christine M Freeman
Journal:  Am J Pathol       Date:  2015-01-07       Impact factor: 4.307

3.  Oxidative stress causes muscle structural alterations via p38 MAPK signaling in COPD mouse model.

Authors:  Yosuke Mano; Manabu Tsukamoto; Ke-Yong Wang; Takayuki Nabeshima; Kenji Kosugi; Takafumi Tajima; Yoshiaki Yamanaka; Hitoshi Suzuki; Makoto Kawasaki; Eiichiro Nakamura; Qian Zhou; Kagaku Azuma; Tamiji Nakashima; Yuki Tamura; Karina Kozaki; Koichi Nakazato; Yun-Shan Li; Kazuaki Kawai; Kazuhiro Yatera; Akinori Sakai
Journal:  J Bone Miner Metab       Date:  2022-09-26       Impact factor: 2.976

4.  The BRD4 inhibitor JQ1 protects against chronic obstructive pulmonary disease in mice by suppressing NF-κB activation.

Authors:  Yan Liu; Zhi-Zhen Huang; Li Min; Zhi-Feng Li; Kui Chen
Journal:  Histol Histopathol       Date:  2020-11-20       Impact factor: 2.303

5.  Gallic acid ameliorates COPD-associated exacerbation in mice.

Authors:  Esha Singla; Gayatri Puri; Vivek Dharwal; Amarjit S Naura
Journal:  Mol Cell Biochem       Date:  2020-09-23       Impact factor: 3.396

Review 6.  Immunodeficiency in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

Authors:  Sheling Xie; Kaifei Wang; Wei Zhang; Kun Xiao; Peng Yan; Yanqin Li; Wanxue He; Yuhan Zhang; Lixin Xie
Journal:  Inflammation       Date:  2018-10       Impact factor: 4.092

7.  Domestic exposure to endotoxin and respiratory morbidity in former smokers with COPD.

Authors:  S Bose; F Rivera-Mariani; R Chen; D Williams; A Belli; C Aloe; M C McCormack; P N Breysse; N N Hansel
Journal:  Indoor Air       Date:  2015-12-14       Impact factor: 5.770

Review 8.  Animal Models Reflecting Chronic Obstructive Pulmonary Disease and Related Respiratory Disorders: Translating Pre-Clinical Data into Clinical Relevance.

Authors:  Lloyd Tanner; Andrew Bruce Single
Journal:  J Innate Immun       Date:  2019-09-17       Impact factor: 7.349

9.  A gene therapy induced emphysema model and the protective role of stem cells.

Authors:  Paul Zarogoulidis; Wolfgang Hohenforst-Schmidt; Haidong Huang; Despoina Sahpatzidou; Lutz Freitag; Leonidas Sakkas; Aggeliki Rapti; Ioannis Kioumis; Georgia Pitsiou; Kokkona Kouzi-Koliakos; Anna Papamichail; Antonis Papaiwannou; Theodora Tsiouda; Kosmas Tsakiridis; Konstantinos Porpodis; Sofia Lampaki; John Organtzis; Andreas Gschwendtner; Konstantinos Zarogoulidis
Journal:  Diagn Pathol       Date:  2014-11-14       Impact factor: 2.644

10.  Development and multimodal characterization of an elastase-induced emphysema mouse disease model for the COPD frequent bacterial exacerbator phenotype.

Authors:  Irene Rodríguez-Arce; Xabier Morales; Mikel Ariz; Begoña Euba; Nahikari López-López; Maider Esparza; Derek W Hood; José Leiva; Carlos Ortíz-de-Solórzano; Junkal Garmendia
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.